Comparison of candidate gene expression between the subgroups VH-MUT, VH-UM, and V3-21 and V1-69 and VH-UM
Gene . | VH-UM vs VH-MUT . | V3-21 vs VH-MUT . | V3-21 vs VH-UM . | V1-69 vs VH-UM . |
|---|---|---|---|---|
| Non–CD19-purified cohort | ||||
| AKT | 0.62 (0.45, 1.0) | 0.84 (0.6, 1.2) | 1.2 (0.8, 2.1) | 0.83 (0.58, 1.3) |
| ATM | 0.57 (0.33, 0.97) | 0.66 (0.47, 0.93) | 1.2 (0.69, 2.1) | 0.81 (0.44, 1.4) |
| BAX | 1.4 (1.0, 1.9)* | 0.75 (0.44, 1.1) | 0.55 (0.38, 0.73)* | 0.76 (0.57, 1.0) |
| BLNK | 1.0 (0.66, 1.5) | 0.77 (0.49, 1.2) | 0.8 (0.5, 1.2) | 0.51 (0.32, 0.8)* |
| CCND1 | 0.61 (0.4, 0.94) | 0.66 (0.43, 0.94) | 1.0 (0.69, 1.6) | 1.2 (0.72, 2.0) |
| CCND2 | 2.1 (1.3, 3.2)* | 0.58 (0.4, 0.8)* | 0.27 (0.17, 0.44)* | 0.8 (0.47, 1.4) |
| CCND3 | 1.4 (0.91, 1.9) | 0.7 (0.42, 1.2) | 0.51 (0.32, 0.95) | 0.72 (0.46, 1.0) |
| CDK4 | 1.6 (1.1, 3.3)* | 0.69 (0.42, 1.5) | 0.43 (0.27, 0.71)* | 0.32 (0.17, 0.62)* |
| FADD | 0.8 (0.55, 1.2) | 1.1 (0.74, 1.5) | 1.3 (0.88, 1.9) | 1.1 (0.71, 1.7) |
| JAK3 | 1.2 (0.86, 1.7) | 0.82 (0.56, 1.2) | 0.66 (0.49, 0.87) | 0.74 (0.57, 0.98) |
| LYN | 1.1 (0.7, 1.8) | 0.78 (0.56, 1.2) | 0.73 (0.42, 1.2) | 0.92 (0.58, 1.5) |
| MYC | 1.0 (0.6, 2.0) | 0.84 (0.46, 1.4) | 0.78 (0.43, 1.4) | 0.96 (0.46, 1.9) |
| NFKB | 1.4 (1.0, 2.4) | 0.87 (0.57, 1.1) | 0.58 (0.34, 0.88) | 1.3 (0.82, 2.0) |
| P27 | 0.98 (0.75, 1.2) | 0.63 (0.5, 0.83)* | 0.65 (0.51, 0.85)* | 1.1 (0.94, 1.5) |
| PI3K | 1.7 (1.2, 2.7)* | 0.77 (0.57, 1.1) | 0.44 (0.28, 0.66)* | 0.7 (0.47, 1.1) |
| PLCG2 | 0.75 (0.53, 1.1) | 0.7 (0.48, 0.98) | 0.93 (0.67, 1.4) | 0.78 (0.53, 1.1) |
| STAT6 | 0.95 (0.69, 1.4) | 0.96 (0.64, 1.4) | 0.98 (0.67, 1.4) | 0.64 (0.44, 1.0) |
| SYK | 1.1 (0.79, 1.4) | 0.69 (0.36, 1.1) | 0.63 (0.34, 1.0) | 0.57 (0.45, 0.8)* |
| TP53 | 1.3 (0.9, 1.9) | 0.77 (0.52, 1.2) | 0.57 (0.4, 0.82) | 0.49 (0.32, 0.8)* |
| TRAF3 | 0.64 (0.46, 0.95) | 0.87 (0.62, 1.3) | 1.4 (0.94, 2.1) | 1.3 (0.77, 2.1) |
| CD19-purified cohort | ||||
| BCL2 | 0.78 (0.51, 1.2) | 0.8 (0.29, 1.3) | 1.0 (0.36, 1.8) | 0.92 (0.51, 1.7) |
| BCLXL | 0.68 (0.49, 0.96) | 1 (0.45, 2.2) | 1.4 (0.63, 3.2) | 0.86 (0.59, 1.3) |
| E2F1 | 0.8 (0.24, 3.0) | 0.77 (0.37, 1.6) | 1.1 (0.58, 2.2) | 1.1 (0.61, 1.6) |
| FOS | 0.67 (0.43, 1.1) | 1.2 (0.48, 5.4) | 1.7 (0.56, 5.2) | 3.7 (1.5, 9.8)* |
| LCK | 0.92 (0.5, 2.1) | 1.4 (0.66, 3.3) | 1.3 (0.73, 2.9) | 0.65 (0.38, 1.3) |
| ZAP70 | 5.8 (2.6, 14)* | 9.3 (3.5, 25)* | 1.5 (0.75, 3.2) | 0.74 (0.36, 1.4) |
Gene . | VH-UM vs VH-MUT . | V3-21 vs VH-MUT . | V3-21 vs VH-UM . | V1-69 vs VH-UM . |
|---|---|---|---|---|
| Non–CD19-purified cohort | ||||
| AKT | 0.62 (0.45, 1.0) | 0.84 (0.6, 1.2) | 1.2 (0.8, 2.1) | 0.83 (0.58, 1.3) |
| ATM | 0.57 (0.33, 0.97) | 0.66 (0.47, 0.93) | 1.2 (0.69, 2.1) | 0.81 (0.44, 1.4) |
| BAX | 1.4 (1.0, 1.9)* | 0.75 (0.44, 1.1) | 0.55 (0.38, 0.73)* | 0.76 (0.57, 1.0) |
| BLNK | 1.0 (0.66, 1.5) | 0.77 (0.49, 1.2) | 0.8 (0.5, 1.2) | 0.51 (0.32, 0.8)* |
| CCND1 | 0.61 (0.4, 0.94) | 0.66 (0.43, 0.94) | 1.0 (0.69, 1.6) | 1.2 (0.72, 2.0) |
| CCND2 | 2.1 (1.3, 3.2)* | 0.58 (0.4, 0.8)* | 0.27 (0.17, 0.44)* | 0.8 (0.47, 1.4) |
| CCND3 | 1.4 (0.91, 1.9) | 0.7 (0.42, 1.2) | 0.51 (0.32, 0.95) | 0.72 (0.46, 1.0) |
| CDK4 | 1.6 (1.1, 3.3)* | 0.69 (0.42, 1.5) | 0.43 (0.27, 0.71)* | 0.32 (0.17, 0.62)* |
| FADD | 0.8 (0.55, 1.2) | 1.1 (0.74, 1.5) | 1.3 (0.88, 1.9) | 1.1 (0.71, 1.7) |
| JAK3 | 1.2 (0.86, 1.7) | 0.82 (0.56, 1.2) | 0.66 (0.49, 0.87) | 0.74 (0.57, 0.98) |
| LYN | 1.1 (0.7, 1.8) | 0.78 (0.56, 1.2) | 0.73 (0.42, 1.2) | 0.92 (0.58, 1.5) |
| MYC | 1.0 (0.6, 2.0) | 0.84 (0.46, 1.4) | 0.78 (0.43, 1.4) | 0.96 (0.46, 1.9) |
| NFKB | 1.4 (1.0, 2.4) | 0.87 (0.57, 1.1) | 0.58 (0.34, 0.88) | 1.3 (0.82, 2.0) |
| P27 | 0.98 (0.75, 1.2) | 0.63 (0.5, 0.83)* | 0.65 (0.51, 0.85)* | 1.1 (0.94, 1.5) |
| PI3K | 1.7 (1.2, 2.7)* | 0.77 (0.57, 1.1) | 0.44 (0.28, 0.66)* | 0.7 (0.47, 1.1) |
| PLCG2 | 0.75 (0.53, 1.1) | 0.7 (0.48, 0.98) | 0.93 (0.67, 1.4) | 0.78 (0.53, 1.1) |
| STAT6 | 0.95 (0.69, 1.4) | 0.96 (0.64, 1.4) | 0.98 (0.67, 1.4) | 0.64 (0.44, 1.0) |
| SYK | 1.1 (0.79, 1.4) | 0.69 (0.36, 1.1) | 0.63 (0.34, 1.0) | 0.57 (0.45, 0.8)* |
| TP53 | 1.3 (0.9, 1.9) | 0.77 (0.52, 1.2) | 0.57 (0.4, 0.82) | 0.49 (0.32, 0.8)* |
| TRAF3 | 0.64 (0.46, 0.95) | 0.87 (0.62, 1.3) | 1.4 (0.94, 2.1) | 1.3 (0.77, 2.1) |
| CD19-purified cohort | ||||
| BCL2 | 0.78 (0.51, 1.2) | 0.8 (0.29, 1.3) | 1.0 (0.36, 1.8) | 0.92 (0.51, 1.7) |
| BCLXL | 0.68 (0.49, 0.96) | 1 (0.45, 2.2) | 1.4 (0.63, 3.2) | 0.86 (0.59, 1.3) |
| E2F1 | 0.8 (0.24, 3.0) | 0.77 (0.37, 1.6) | 1.1 (0.58, 2.2) | 1.1 (0.61, 1.6) |
| FOS | 0.67 (0.43, 1.1) | 1.2 (0.48, 5.4) | 1.7 (0.56, 5.2) | 3.7 (1.5, 9.8)* |
| LCK | 0.92 (0.5, 2.1) | 1.4 (0.66, 3.3) | 1.3 (0.73, 2.9) | 0.65 (0.38, 1.3) |
| ZAP70 | 5.8 (2.6, 14)* | 9.3 (3.5, 25)* | 1.5 (0.75, 3.2) | 0.74 (0.36, 1.4) |
Comparison of candidate gene expression between the subgroups VH-MUT, VH-UM, and V3-21 (Kruskal-Wallis test for 3-group comparisons) and between V1-69 and VH-UM (Wilcoxon rank-sum test statistics for pair-wise comparisons). The numbers for the non–CD19-purified cohort are VH-UM versus VH-MUT, 19 and 17, respectively; for V3-21 versus VH-MUT, 16 versus 17; for V3-21 versus VH-UM, 16 versus 19; and for V1-69 versus VH-UM, 17 versus 19. For the CD19-purified cohort, the respective numbers are 21 versus 12, 8 versus 12, 8 versus 21, and 12 versus 21. Data presented are fold expression changes with the corresponding 95% CIs (lower and upper confidence limits).
Significant expression differences after P adjustment